Johnson & Johnson : Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

RARITAN, NJ,May 30, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a New Drug Application to the U.S. Food and Drug Administration ... | May 30, 2023

Related Keywords

Argentina ,Canada ,Shelly Orlacchio ,Tina Kitt ,World Health Organization Group ,Janssen Research Development ,Companies Of Johnson ,European Society Of Cardiology Respiratory ,Drug Administration ,Janssen Pharmaceutical Companies Of Johnson ,None Of The Janssen Pharmaceutical Companies ,Johnson ,Exchange Commission ,Pulmonary Hypertension At Janssen Research Development ,Janssen Pharmaceutical Companies ,New Drug Application ,World Health Organization ,Global Therapeutic Area Head ,Pulmonary Hypertension ,Janssen Research ,European Society ,European Respiratory Society ,Medication Guide ,Risk Evaluation ,Mitigation Strategy ,Prescribing Information ,Important Warning ,Serious Birth Defects ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Heart Journal ,Johnson Stock Exchange ,News ,Information ,Press Release ,023 ,The ,Janssen ,Harmaceutical ,Companies ,F ,Nnounced ,Oday ,Submission ,Few ,Drug ,Application ,O ,Wood ,End ,Dministration Jnj Us4781601046 ,